Get the Stockscreener App
29.77
3.22%
-0.99
After Hours:
31.50
1.73
+5.81%
Lenz Therapeutics Inc stock is traded at $29.77, with a volume of 273.42K.
It is down -3.22% in the last 24 hours and up +1.57% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$30.76
Open:
$30.55
24h Volume:
273.42K
Relative Volume:
1.02
Market Cap:
$837.91M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-5.3186
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-10.87%
1M Performance:
+1.57%
6M Performance:
+16.61%
1Y Performance:
+19.90%
1-Day Range:
$29.71
$31.41
1-Week Range:
$29.71
$34.86
52-Week Range:
$16.54
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
29.77 | 865.78M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia - VisionMonday.com
How many analysts rate LENZ Therapeutics Inc. as a “Buy”Wealth Building Trend Scanner For Smart Trading - jammulinksnews.com
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops - Investing.com Australia
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops By Investing.com - Investing.com India
FDA Approval: Revolutionary 10-Hour Eye Drops Promise Freedom from Reading Glasses - Stock Titan
Lenz (LENZ) Q2 Revenue Jumps 604% - The Motley Fool
Lenz Therapeutics Prepares for LNZ100 Launch - TipRanks
Is a relief rally coming for LENZ Therapeutics Inc. holdersFree AI Powered High Return Stock Calls - Newser
FY2025 EPS Estimate for LENZ Therapeutics Lifted by Analyst - Defense World
How volatile is LENZ Therapeutics Inc. stock compared to the marketStock Strategy Insights For Fast Growth - jammulinksnews.com
LENZ Therapeutics gains on NDA submission in China for presbyopia drug LNZ100 - MSN
LENZ Therapeutics shares climb as FDA review of presbyopia treatment stays on schedule - MSN
LENZ Therapeutics shares surge as FDA review of presbyopia drug on track - Investing.com Nigeria
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss - Yahoo Finance
LENZ Therapeutics and the Imminent FDA Decision for LNZ100: A High-Conviction Biotech Play Ahead of PDUFA - AInvest
LENZ Therapeutics Preps Launch of First Aceclidine Eye Drops: FDA Decision in 9 Days, $195M Global Deals Secured - Stock Titan
What makes LENZ Therapeutics Inc. stock price move sharplyBuy and Hold Return Summary with Charts - Newser
Has LENZ Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewMomentum-Based Prediction for Quick Returns - Newser
Why LENZ Therapeutics Inc. stock attracts strong analyst attentionWeekly Trend Screener with Momentum Picks - Newser
Using data models to predict LENZ Therapeutics Inc. stock movementAI Risk Optimized Trade Forecast Planner - Newser
Will LENZ Therapeutics Inc. benefit from macro trendsEquity Portfolio Outlook and Performance Summary - Newser
How Efficient Is LENZ Therapeutics Inc. at Controlling Operating CostsStrong Buy With Technical Confidence Supported - metal.it
Has LENZ Therapeutics Inc. found a price floorFree Capital Efficiency Optimized Stock Alerts - Newser
LENZ Therapeutics: Undervalued Ahead Of PDUFA (NASDAQ:LENZ) - Seeking Alpha
Published on: 2025-07-29 12:30:28 - metal.it
LENZ Therapeutics (NASDAQ:LENZ) Receives Buy Rating from HC Wainwright - Defense World
CORXEL submits NDA for LNZ100 in China for presbyopia treatment - Ophthalmology Times
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia - The Manila Times
H.C. Wainwright raises LENZ Therapeutics stock price target to $48 ahead of FDA decision - Investing.com India
LENZ's Breakthrough Presbyopia Eye Drop Heads to China FDA with $95M Milestone Potential - Stock Titan
Is a relief rally coming for LENZ Therapeutics Inc. holders Free Oversold Recovery Opportunity Stocks - Newser
What are LENZ Therapeutics Inc. company’s key revenue driversFree Investment Case Studies - jammulinksnews.com
What are the latest earnings results for LENZ Therapeutics Inc.Skyrocketing profit margins - jammulinksnews.com
Is LENZ Therapeutics Inc. a growth stock or a value stockBreakneck growth rates - jammulinksnews.com
How does LENZ Therapeutics Inc. generate profit in a changing economyInvest smarter and grow your wealth faster - jammulinksnews.com
How strong is LENZ Therapeutics Inc. company’s balance sheetTriple-digit wealth increases - jammulinksnews.com
What is the dividend policy of LENZ Therapeutics Inc. stockNavigate market shifts with confidence - jammulinksnews.com
How LENZ Therapeutics Inc. stock performs during market volatilityFree Stock Movement Tracking - Newser
What analysts say about LENZ Therapeutics Inc. stockMarket-leading growth rates - PrintWeekIndia
LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional
Is LENZ Therapeutics Inc. a good long term investmentTremendous growth potential - PrintWeekIndia
Analysts Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Target Price at $46.60 - Defense World
All Eyes On LENZWill The Regulatory Catalyst Ignite A Rally Or Sink The Stock? - RTTNews
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):